GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Capital Expenditure

TNDM (Tandem Diabetes Care) Capital Expenditure : $-43.65 Mil (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Tandem Diabetes Care's cash flow for capital expenditures for the three months ended in Sep. 2024 was $-5.2 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was $-43.65 Mil.

Tandem Diabetes Care Capital Expenditure Historical Data

The historical data trend for Tandem Diabetes Care's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Capital Expenditure Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.54 -32.29 -23.51 -42.95 -51.60

Tandem Diabetes Care Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.40 -27.48 -4.46 -6.47 -5.24

Tandem Diabetes Care Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Capital Expenditure
Comparable Companies
UFPT TMDX ATEC AHCO PRCT SSII NVCR AVNS ESTA QTRX ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
0M0F:UK TD5A:Germany
Address
12400 High Bluff Drive, San Diego, CA, USA, 92130
Website
https://www.tandemdiabetes.com
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121